FY2025 · period end Dec '25 · from the 10-K filed Mar 18, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0.09B | $0.00B | $0.02B | $0.00B | $0.02B |
| Gross Profit | — | — | — | — | — |
| Operating Income | negative: -$0.16B | negative: -$0.19B | negative: -$0.11B | negative: -$0.11B | negative: -$0.07B |
| Net Income | negative: -$0.14B | negative: -$0.16B | negative: -$0.10B | negative: -$0.11B | negative: -$0.07B |
| EPS (Diluted) | negative: -$2.42 | negative: -$2.98 | negative: -$2.58 | negative: -$3.32 | negative: -$2.57 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $0.57B | $0.56B | $0.34B | $0.26B | $0.35B |
| Total Liabilities | $0.06B | $0.05B | $0.03B | $0.03B | $0.03B |
| Stockholders' Equity | $0.51B | $0.51B | $0.31B | $0.23B | $0.32B |
| Cash & Equivalents | $0.06B | $0.15B | $0.25B | $0.05B | $0.15B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | negative: -$0.11B | negative: -$0.13B | negative: -$0.08B | negative: -$0.09B | negative: -$0.07B |
| Capital Expenditures | $0.00B | $0.00B | $0.00B | $0.01B | $0.01B |
| Free Cash Flow | negative: -$0.11B | negative: -$0.14B | negative: -$0.08B | negative: -$0.10B | negative: -$0.08B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | negative: -1.9% | negative: -507678.4% | negative: -5.4% | negative: -3516.5% | negative: -4.0% |
| Net Margin | negative: -1.6% | negative: -434778.4% | negative: -4.9% | negative: -3435.4% | negative: -4.0% |
| Return on Equity | negative: -27.6% | negative: -39.3% | negative: -37.4% | negative: -39.1% | negative: -24.8% |
| Return on Assets | negative: -24.9% | negative: -35.7% | negative: -33.5% | negative: -34.9% | negative: -22.2% |
| Debt / Equity | — | — | — | — | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001193125-26-349160 | Aug 13, 2026 | Aug 13, 2026 | Aug 13, 2026 20:06 UTC | EDGAR |
| 10-Q | 0001193125-26-349173 | Jun 30, 2026 | Aug 13, 2026 | Aug 13, 2026 20:09 UTC | EDGAR |
| 8-K | 0001193125-26-308409 | Jul 18, 2026 | Jul 20, 2026 | Jul 20, 2026 12:30 UTC | EDGAR |
| 8-K | 0001193125-26-286880 | Jun 24, 2026 | Jun 29, 2026 | Jun 29, 2026 12:05 UTC | EDGAR |
| 8-K | 0001193125-26-277563 | Jun 17, 2026 | Jun 22, 2026 | Jun 22, 2026 20:21 UTC | EDGAR |
| 10-Q | 0001193125-26-211939 | Mar 31, 2026 | May 7, 2026 | May 7, 2026 20:13 UTC | EDGAR |
| 8-K | 0001193125-26-211904 | May 7, 2026 | May 7, 2026 | May 7, 2026 20:10 UTC | EDGAR |
| 8-K | 0001193125-26-131739 | Mar 25, 2026 | Mar 30, 2026 | Mar 30, 2026 21:29 UTC | EDGAR |
Direct links to SEC EDGAR. FDMT has additional filings available on the SEC site.
Who is buying and selling 4D Molecular Therapeutics, Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on FDMT yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on FDMT and publish the result to your public profile.
Ask about 4D Molecular Therapeutics, Inc.
Continue in Workspace — cited answers on FDMT, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs